• Morgan Stanley maintains an "Overweight" rating for NASDAQ:PHVS, raising its price target from $37 to $41.
• Pharvaris' RAPIDe-3 Phase III study of Deucrictibant shows promising results for treating Hereditary Angioedema (HAE), with a median time to symptom relief of just 1.28 hours.
• The company plans to use the study data for marketing authorization applications, starting in the first half of 2026, as the stock value increases by 21.75%.

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing innovative treatments for rare diseases. The company is making strides in the pharmaceutical market, particularly with its treatment for Hereditary Angioedema (HAE), a rare genetic disorder. As of December 3, 2025, Morgan Stanley maintained an "Overweight" rating for PHVS, with the stock priced at $29.37. The firm also raised its price target from $37 to $41, as highlighted by TheFly.

The recent release of topline data from Pharvaris' RAPIDe-3 Phase III study of Deucrictibant marks a significant milestone. This study evaluated the efficacy of deucrictibant for treating HAE attacks, a condition causing severe swelling in various body parts. The trial involved 134 participants aged 12 and older, and the results showed a faster median time to onset of treatment compared to a placebo. This promising data is crucial for Pharvaris as it progresses in its clinical trials.

Pharvaris plans to use the RAPIDe-3 study data as the foundation for marketing authorization applications, expected to be submitted starting in the first half of 2026. The positive results have contributed to an increase in PHVS stock value. The study met its primary endpoint, with a median time to symptom relief of just 1.28 hours, significantly faster than the placebo. Notably, 83% of attacks were treated with a single capsule, and 93.2% did not require rescue medication within 12 hours.

Marc A. Riedl, M.D., M.S., a principal investigator in the RAPIDe-3 study, emphasized the effectiveness of bradykinin B2 receptor antagonism in treating bradykinin-mediated angioedema. Despite available therapies, unmet medical needs remain, highlighting the importance of effective, well-tolerated, and convenient acute treatments for HAE. This development positions Pharvaris as a key player in addressing these needs.

Currently, PHVS is priced at $29.37, reflecting a 21.75% increase with a change of $5.25. The stock has fluctuated between $23.80 and $29.68 today, with a 52-week high of $29.67 and a low of $11.51. Pharvaris' market capitalization is approximately $1.91 billion, with a trading volume of 3,539,819 shares.